Recursion to Host Public L(earnings) Call on February 27
20 Février 2024 - 1:59PM
Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company
decoding biology to industrialize drug discovery, announced today
it will provide business updates and report its fourth quarter and
full year 2023 financial results on Tuesday, February 27, 2024,
following the close of the financial markets.
Additionally, Recursion will host its
first-ever L(earnings) Call on February 27,
2024 at 5:00 pm Eastern Time / 3:00 pm Mountain Time. A L(earnings)
Call is Recursion’s take on interacting with a broad public
audience around notable business developments and offering
opportunities to ask questions. Recursion will broadcast the live
stream from Recursion’s X (formerly Twitter), LinkedIn and YouTube
accounts. This event is free, open to the public and encouraged,
especially for those wishing to ask questions. Questions can be
submitted at https://bit.ly/3usHrwR.
About Recursion
Recursion (NASDAQ: RXRX) is a clinical stage TechBio company
leading the space by decoding biology to industrialize drug
discovery. Enabling its mission is the Recursion OS, a platform
built across diverse technologies that continuously expands one of
the world’s largest proprietary biological and chemical datasets.
Recursion leverages sophisticated machine-learning algorithms to
distill from its dataset a collection of trillions of searchable
relationships across biology and chemistry unconstrained by human
bias. By commanding massive experimental scale — up to millions of
wet lab experiments weekly — and massive computational scale —
owning and operating one of the most powerful supercomputers in the
world, Recursion is uniting technology, biology and chemistry to
advance the future of medicine.
Recursion is headquartered in Salt Lake City, where it is a
founding member of BioHive, the Utah life sciences industry
collective. Recursion also has offices in Toronto, Montréal and the
San Francisco Bay Area. Learn more at www.Recursion.com, or connect
on X (formerly Twitter) and LinkedIn.
Forward-Looking Statements
This document contains information that includes or is based
upon "forward-looking statements" within the meaning of the
Securities Litigation Reform Act of 1995, including, without
limitation, those regarding early and late stage discovery,
preclinical, and clinical programs; licenses and collaborations;
prospective products and their potential future indications and
market opportunities; Recursion OS and other technologies; business
and financial plans and performance; and all other statements that
are not historical facts. Forward-looking statements may or may not
include identifying words such as “plan,” “will,” “expect,”
“anticipate,” “intend,” “believe,” “potential,” “continue,” and
similar terms. These statements are subject to known or unknown
risks and uncertainties that could cause actual results to differ
materially from those expressed or implied in such statements,
including but not limited to: challenges inherent in pharmaceutical
research and development, including the timing and results of
preclinical and clinical programs, where the risk of failure is
high and failure can occur at any stage prior to or after
regulatory approval due to lack of sufficient efficacy, safety
considerations, or other factors; our ability to leverage and
enhance our drug discovery platform; our ability to obtain
financing for development activities and other corporate purposes;
the success of our collaboration activities; our ability to obtain
regulatory approval of, and ultimately commercialize, drug
candidates; our ability to obtain, maintain, and enforce
intellectual property protections; cyberattacks or other
disruptions to our technology systems; our ability to attract,
motivate, and retain key employees and manage our growth; inflation
and other macroeconomic issues; and other risks and uncertainties
such as those described under the heading “Risk Factors” in our
filings with the U.S. Securities and Exchange Commission, including
our Annual Report on Form 10-K. All forward-looking statements are
based on management’s current estimates, projections, and
assumptions, and Recursion undertakes no obligation to correct or
update any such statements, whether as a result of new information,
future developments, or otherwise, except to the extent required by
applicable law.
Media Contact
Media@Recursion.com
Investor Contact
Investor@Recursion.com
Recursion Pharmaceuticals (NASDAQ:RXRX)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Recursion Pharmaceuticals (NASDAQ:RXRX)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024